Skip to main content
OpenTrials
Completed

NCT Number: NCT03645070

Randomized Study on the Effect of Oesophageal Temperature on the Incidence of Esophageal Lesions After AF Ablation

It's a randomized pilot study to evaluate the incidence of esophageal thermal injury after left atrial ablation for the treatment of atrial fibrillation according to three different strategies of esophageal temperature monitoring.

These patients will be divided into 3 groups with different strategies of esophageal temperature monitoring: group 1 without monitoring, group 2 monitoring with single probe thermometer and group 3 monitoring with multi-probe thermometer.

The primary end point will be the incidence of esophageal lesions assessed by upper endoscopy.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Arrhythmia Clinical Unit - Instituto do Coração - HCFMUSP

São Paulo, 05403010, Brazil

About this study

This is a randomized pilot study on the effect of oesophageal temperature monitoring on the esophageal thermal injury after left atrial ablation for the treatment of atrial fibrillation (AF).

Sixty patients with paroxysmal AF or persistent and without previous AF ablation with indication of AF ablation will be selected to be included at the study.

After informed consent, these patients will be randomized in 3 groups with different strategies of esophageal protection for radiofrequency application in the posterior wall of the left atrium, by randomization in a ratio of 1: 1: 1 between groups.

Group I: no esophageal temperature monitoring technique. Group II: monitoring of esophageal temperature during radiofrequency applications in the posterior wall of the left atrium, with unipolar thermometer.

Group III: oesophageal temperature monitoring during radiofrequency applications in the posterior wall of the left atrium, with a multipolar and self expandable thermometer.

The primary end point will be the incidence of esophageal lesions assessed by upper endoscopy that will be done in all patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with paroxysmal or persistent AF, diagnosed by electrocardiogram, 24-hour Holter, or monitors of implantable or non-implantable events, with at least one episode of AF up to 12 months before the procedure. Patients should be willing and able to sign an informed consent form, and to undergo all procedures described in both the study protocol and the consent form.

Exclusion criteria

  • Atrial thrombus in the left atrium, history of AF ablation, history of cardiac surgery, contraindication to anticoagulation, permanent AF, New York Heart Association functional class III or IV, stroke in the last 3 months, pregnancy, history blood clotting abnormalities, previous oesophageal surgery, or advanced chronic kidney disease (creatinine > 2.5 mg/dl).

Treatment and study plan

multipolar and self expandable thermometer

Device

Will be evaluated if a multipolar and self expandable thermometer is superior to no probe or to single probe thermometer at prevention of esophageal thermal injury.

Other names: CIRCA's S-CATH™ Esophageal Temperature Monitoring System

Single probe thermometer

Device

Will be evaluated if a single probe thermometer is superior to a multipolar and self expandable thermometer or to no probe thermometer at prevention of esophageal thermal injury

Primary outcomes

  1. Incidence of esophageal lesions

    Time frame: Within three days after the ablation procedure.

    Incidence of esophageal lesions evaluated by upper digestive endoscopy

Secondary outcomes

  1. Rate of recurrence of AF

    Time frame: Six months

    Rate of recurrence of AF after ablation assessed by ECG, Holter 24 hours or clinically.

  2. Isolation rate of pulmonary veins at the end of ablation.

    Time frame: End of the procedure

    Will be assessed the rate of pulmonary veins isolation

  3. Duration of the AF ablation procedure

    Time frame: End of the procedure

    Will be assessed the duration of the AF ablation that will start at the time of the first radio-frequency lesion until the last one.

  4. Incidence of atrio-esophageal fistulas

    Time frame: Six months

    Incidence of atrio-esophageal fistulas after AF ablation

  5. Difference in the size of the esophageal lesions

    Time frame: Within three days

    Difference in the size of the esophageal lesions evaluated in the upper digestive endoscopy according to the different groups

  6. Persistence of esophageal lesions in the second upper endoscopy.

    Time frame: Between 3 to 30 days of the procedure

    If necessary, the patients with esophageal lesions will be submitted to another upper endoscopy, and the persistence of esophageal lesions will be assessed

  7. Maximum esophageal temperature reached during ablation.

    Time frame: During procedure.

    In the groups with esophageal temperature monitoring, the maximum esophageal temperature will be assessed and evaluated between two arms.

Sponsors and collaborators

Lead sponsor

University of Sao Paulo General Hospital

Other

Collaborators

  • Circa Scientific, Inc.

Registry information

Official study title

A Prospective Randomized Study on the Effect of Oesophageal Temperature Monitoring on the Incidence of Esophageal Lesions After Left Atrial Ablation for the Treatment of Atrial Fibrillation.

Important dates

Study start
2017
Primary completion
2018
Study completion
2020
First posted
Aug 24, 2018
Registry last updated
Jan 10, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.